Last $4.73 USD
Change Today -0.08 / -1.66%
Volume 394.1K
IMMU On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IMMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - $5.44
52 Week Low
05/8/14 - $3.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOMEDICS INC (IMMU)

immunomedics inc (IMMU) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IMMU) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IMMU) Details

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

120 Employees
Last Reported Date: 08/25/14
Founded in 1982

immunomedics inc (IMMU) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $618.9K
Founder, Chairman of The Board and Director o...
Total Annual Compensation: $584.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $235.5K
Total Annual Compensation: $56.6K
Compensation as of Fiscal Year 2014.

immunomedics inc (IMMU) Key Developments

Immunomedics Inc. Reports Phase 1/2 Results with Sacituzumab Govitecan

Immunomedics Inc. announced that sacituzumab govitecan, the company's lead investigational antibody-drug conjugate (ADC), produces partial response (PR) in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated. Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases. Response and TTP were evaluated by computed tomography (CT) based on RECIST criteria. Patented and developed by the company, sacituzumab govitecan was created by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to antibody to a humanized antibody that targets the TROP-2 receptor expressed by many solid cancers. SN-38 is the active metabolite of irinotecan (Camptosar), which is used to treat certain solid cancers, particularly metastatic colorectal cancers, as a part of combination therapies, so its pharmacology and properties are well-known. A total of 63 patients with various types of gastrointestinal cancers had been enrolled into this multicenter study. At the time of analysis, 26 patients with colorectal cancer, 13 with esophageal cancer, 3 with gastric cancer and 14 with pancreatic cancer were evaluated by CT for response and TTP. Median numbers of prior treatments ranged from 2 for pancreatic cancer to 4 in colorectal cancer. Despite the late-stage setting, 1 patient in each of the colorectal and esophageal cancer groups had a partial response after receiving more than 2 doses of the ADC. For all 4 cancer types, the disease stabilization rate (partial response + stable disease) exceeded 50%. Repeated cycles of therapy with sacituzumab govitecan over many months were well tolerated by patients and did not produce the typical side effects of irinotecan treatment other than neutropenia. Transient neutropenia was the major toxicity (18% Grade 3 and 6% Grade 4), followed by febrile neutropenia 4%, and diarrhea 3% Grade 3.

Immunomedics Inc. Appoints Francois E. Wilhelm as Chief Medical Officer

Immunomedics Inc. announced the appointment of Francois E. Wilhelm as Chief Medical Officer of the company. Dr. Wilhelm is a seasoned R&D Senior Executive with significant experience in Oncology and Rheumatology in both the United States and Europe. Francois is an industry veteran with 29 years of global clinical experience in large, multinational pharmaceutical companies and small biotech enterprises alike. Dr. Wilhelm most recently served as Chief Medical Officer and Senior Vice President at Onconova Therapeutics Inc. Previously, Dr. Wilhelm led clinical development programs at Fujisawa, Pfizer, Procter & Gamble, Akros Pharma, and Johnson and Johnson in the United States, as well as Hoffmann-La Roche in Europe.

Immunomedics Announces Encouraging Results from Phase I/II TNBC Study

Immunomedics Inc. has announced that in Phase I/II study, sacituzumab govitecan, an investigational antibody-drug conjugate, or ADC, continues to produce a partial response, or PR, rate of 30% and a 70% clinical benefit rate, or CBR, defined as PR and stable disease, in patients with metastatic triple-negative breast cancer, or TNBC, who had been heavily pretreated. For patients with PR or stable disease longer than 6 months, the CBR was 40%. Significantly, PRs ranging from 30% to 70% tumor shrinkage as best response were reported. Responses are measured by computed tomography (CT) based on RECIST 1.1 criteria. Dr. Aditya Bardia of Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, presented the Phase I/II study.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMU:US $4.73 USD -0.08

IMMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 95.4x
Price/Book 16.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 88.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at